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ABSTRACT
Background: Drug hypersensitivity is classically divided into IgE mediated and non-IgE mediated disease.
We report a rare case of consequent IgE mediated and non-IgE mediated reactions within the beta lactam
class of antibiotics.
Case Summary: An 84-year-old man developed toxic epidermal necrolysis (TEN) due to ceftriaxone, a third
generation cephalosporin, involving 72% of the body surface area. The patient recovered but within weeks sub-
sequently developed an acute IgE mediated allergic reaction to piperacillintazobactam, an extended spectrum
penicillin. Further IgE RAST revealed positive results to penicillin major determinant.
Discussion: This case demonstrates the complexity of drug hypersensitivity reactions. While it is accepted
that IgE mediated penicillin allergy is a predisposition to cephalosporin allergy, this case displays an unusual
correlation between drug hypersensitivity and drug class. There have been few studies that evaluate the cross
reactivity with penicillin or other beta-lactams in subjects with primary hypersensitivity to cephalosporins. This
clinical scenario emphasizes the need of more studies on cephalosporin allergy in particular as shown by this
case of sequential non-IgE mediated cephalosporin induced TEN reaction pursuant by an IgE mediated penicil-
lin allergy.
KEY WORDS
beta-lactams, cephalosporin, penicillin, toxic epidernal necrolysis
INTRODUCTION
Patients with penicillin allergy are at increased risk
for an allergic reaction to cephalosporins. Pumphrey
et al. described the nature of fatal cephalosporin ana-
phylaxis after penicillin sensitization.1 Conversely, a
documented cephalosporin allergy does not clearly
confer a similar increased risk of penicillin allergy.
Drug hypersensitivity reactions can be classified
within Gell and Coombs immunologic reactions. A
correlation has not been established between IgE me-
diated drug hypersensitivity and the cutaneous erup-
tion spectrum of erythema multiforme. We report a
unique case of toxic epidermal necrolysis (TEN) due
to ceftriaxone involving 72% of the body surface area
including nasal mucosal involvement and lip involve-
ment with subsequent acute IgE mediated skin hy-
persensitivity to an extended spectrum penicillin,
piperacillintazobactam, after previous sensitization
with the same drug.
CLINICAL SUMMARY
An 84-year-old man with a history of coronary artery
disease, seasonal allergic rhinitis, and atopic dermati-
tis presented to the emergency department with
cough and dyspnea for several days. In the past, he
received courses of antibiotics including penicillins
and cephalosporins for treatment of sinusitis without
incident. Initial evaluation revealed mild hypotension,
hypoxia on arterial blood gas (SaO2 = 86% on room
air), and a chest x-ray was remarkable for a left lower
lobe infiltrate. After receiving 4 doses of pipercillin
tazobactam 4.5 g IV over 24 hours in the emergency
room, he was admitted to the ICU with a diagnosis of
sepsis and pneumonia. After 24 hours, pipercillinta-
zobactam was discontinued and antibiotics were
changed to ceftriaxone 2 g IV q 4 hours. No addi-
tional medications were given. Within 12 hours of his
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first dose of ceftriaxone, the patient developed an in-
itially eczematous diffuse dermatitis with scattered
pruritic, erythematous patches and papules. Scaling
erythroderma was noted on various areas of the body
including extensor surfaces of the arms, legs, and
trunks. Approximately 72% of the body surface area
was involved with skin detachment above 30% of the
body surface area and with nasal mucosal involve-
ment, lip involvement, and possible conjunctival in-
volvement. Of note, no hives, ulcers or bullae were
noted.
On day 2 of hospitalization, he developed atrial fib-
rillation with hemodynamic compromise requiring
electrical cardioversion. At this time his rash was
noted to have increasing erythroderma but in a stable
distribution. On day 3 of hospitalization the patient
developed bullae and 2nd degree partial thickness in-
volvement with skin loss on the scrotum, sacrum,
coccyx, and ischium. Wound margins were irregular,
erythematous, and blanched with minimal pressure.
Nikolsky’s sign was negative. The patient was evalu-
ated by dermatologists who concurred with the diag-
nosis of TEN secondary to an acute drug reaction.
Ceftriaxone was discontinued at this time. The pa-
tient’s rash became less erythematous and resolved
over the next week. However, as a nursing home pa-
tient, he was mistakenly dosed with ceftriaxone again
within one week of discharge and developed a similar
exacerbation of his previous eruption. He was treated
immediately with a 60 mg prednisone taper over 7
days with complete resolution of symptoms.
Four weeks after discharge, the patient was re-
evaluated at the emergency room for a low grade
temperature of 99.8, hypotension 8145, tachycar-
dia 111, and oxygen saturation of 84% on room air.
Chest x-ray revealed a new left lower lobe infiltrate.
He received piperacillintazobactam 3.375 mg IV and
within 15 minutes had a diffuse erythematous rash on
his back, neck, arms, and the entire legs bilaterally.
The rash was pruritic with intermittent wheals on the
trunk. Within one hour of drug administration, he be-
came hypotensive, tachycardic and hypoxic to 78%
oxygen saturation. He received decadron 4 mg IV
and was ultimately intubated and placed on mechani-
cal ventilation. He received Ranitidine 150 mg bid,
diphenhydramine 25 mg q6 hrs, and a tapering dose
of hydrocortisone 100 mg q8 hrs for 7 days. His spu-
tum culture grew Staphylococcus aureus and Kleb-
siella which was treated with vancomycin and
amikacin. His rash dramatically improved within 72
hours. He was extubated and discharged back to the
nursing home in stable condition.
PATHOLOGICAL FINDINGS
The patient was evaluated in our allergy clinic as an
outpatient 6 months after discharge. Without avail-
ability of penicillin major determinant, ImmunoCAP
testing for penicillin G (major determinant) and peni-
cillin V (minor determinant) was performed through
ARUP Labs (Salt Lake City, Utah). Penicillin G was
interpreted as Class 3 positive (level 9.41 kUL) and
penicillin V was interpreted as negative (<0.35 kUL).
Based upon the patient’s medical history and lab re-
sults, he was labeled with an IgE mediated penicillin
allergy allowing for desensitization if necessary. How-
ever, the TEN reaction to cephalosporins precluded
the use of this drug class in the future.
DISCUSSION
Drug allergies can be categorized into IgE-mediated
(type Iimmediate-type) and non-IgE mediated hyper-
sensitivity reactions. IgE-mediated reactions include
anaphylaxis, angioedema, urticaria, and bron-
chospasm and occur within 72 hours after drug ad-
ministration. Non-IgE mediated hypersensitivity reac-
tions include hemolytic anemia, interstitial nephritis,
thrombocytopenia, serum sickness, drug fever, mor-
billiform eruptions, erythema multiforme, Stevens-
Johnson syndrome, and toxic epidermal necrolysis
and occur most commonly after 72 hours of drug ad-
ministration.2
TEN is defined as extensive detachment of full-
thickness epidermis most often related to an adverse
drug reaction.3 The mechanism of the TEN phe-
nomenon is not completely understood. Originally, it
was hypothesized that the major factor involved
CD8+ cytotoxic T cells,4,5 although more recently it is
believed that fatty acid synthetase (FAS) and FAS
ligand (FASL) are more responsible for keratinocyte
death.6,7 FASL has been found to be elevated in sera
and expressed on keratinocytes of skin sections from
TEN, SJS, and maculopapular rash although the de-
gree of elevations does not correlate with severity of
skin rash.8 This can interact with FAS (CD95), a
death receptor constitutively expressed on keratino-
cytes and upon crosslinking, results in rapid apopto-
sis.9 TEN is considered a severe form of the
erythema multiforme spectrum. The spectrum is dis-
tinguished by surface area with Steven-Johnson syn-
drome defined by a limit of 10% body surface. Skin
detachment of 10―30% is designated SJS-TEN overlap
syndrome, and TEN is defined by 30% or more skin
detachment.10
Skin reactions in cephalosporin drug allergy are ap-
proximated to occur between 1% to 3% of patients.
However, the overall incidence of severe skin reac-
tions to cephalosporins is lower than with penicil-
lins.11 Case reports of exfoliative dermatitis due to
ceftazidine, cephalexin, cefoxitin and cefotaxime ther-
apy have been published.12-15
While type I hypersensitivity cross reactivity is
known with beta lactams, TEN may occur with both
penicillins and cephalosporins in an undefined
mechanism. IgE mediated crossreactivity between
cephalosporin and penicillins may be due to the beta-
lactam ring, specific side chains, or other unknown
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haptenic determinants. Cephalosporin allergy occurs
in 8.1% of those with a history of penicillin allergy as
compared with 1.9% of those without such a history.16
There have been few studies, however, which have
evaluated the cross reactivity with penicillin or other
beta-lactams in subjects with primary hypersensitivity
to cephalosporins.17,18 Romano et al. determined the
IgE response in subjects with known immediate hy-
persensitivity reactions to cephalosporins and evalu-
ated the cross-reactivity to different cephalosporins
and penicillins. All 30 subjects displayed a history of
immediate reactions to injectable cephalosporins and
positive skin test or RAST to either cephalosporins or
penicillins. Of these 30 subjects, 29 had skin tests
positive for cephalosporins. Of 30 subjects, 86.7% dis-
played skin test negativity to penicillin determinants.
The remaining 13.3% of patients had skin RAST posi-
tive to penicillin determinants (half from penicilloyl-
polylysine and half from ampicilloyl-polylysine). The
former group was further analyzed to be 57.7% posi-
tive to only the culprit cephalosporin and 42.3% posi-
tive to a different non-culprit cephalosporin.19
This case exemplifies the complexity of multiple
drug reactions. This patient was given diagnoses of
several drug reactions in a span of a few weeks. He
had a clear history of atopic skin disease and rhinitis
preceding his first hospitalization. He had previous
exposure to beta-lactam antibiotics without incident
during his lifetime. This history of atopy by itself
does not seem to be an independent risk factor for an-
tibiotic allergy although it may predispose patients to
more severe and even fatal reactions in the event of
anaphylaxis.20
This patient showed evidence of type I hypersensi-
tivity. This patient was sensitized to beta lactams
prior to his first hospitalization. Since he developed
no reaction to penicillin drugs upon initial admission
while receiving zosyn, he was sensitized to penicil-
lins, but not at a high enough antigen load to trigger
an IgE response. However, after the ceftriaxone
based reaction, he became “hypersensitive” to peni-
cillin and developed an acute drug reaction. During
his second hospitalization, he displayed an immediate
type hypersensitivity to pipercillintazobactam which
responded to discontinuation of the drug and anaphy-
laxis therapy. In addition, ImmunoCAP testing sup-
ports the diagnosis.
Of greater interest, this patient appeared to have a
severe exfoliative erythroderma that developed while
on another beta lactam, ceftriaxone. To our knowl-
edge, there have been no case reports linking a type I
hypersensitivity reaction to a beta lactam to that of
TEN. In toxic epidermal necrolysis, T lymphocytes
present at the site of lesions, exhibit a drug specific
cytotoxicity against autologous target cells, or alloge-
neic cells that shared the same HLA than autologous
cells. This MHC class I restriction and mediation of
death by perforingranzyme release, is the classical
behavior of cytotoxic T lymphocytes, like those oper-
ating in the rejection of a transplanted organ. As pre-
viously reported, MHC restriction could explain the
key role of HLA genes as predisposing factors to se-
vere drug reactions. Also, although FASL was not
measured in this patient’s sera, this patient may have
a genetic predisposition leading to an increase of
FASL which has been found to be increased in both
maculopapular rashes, SJS, and TEN. Nevertheless,
the FASFASL hypothesis does not elucidate
whether this patient’s underlying atopic predisposi-
tion conferred a setup for such a response.
Ideally, this patient should have been skin tested to
both major and minor determinants of penicillin.
However, our facility did not have access to these de-
terminants. In addition, with the history of TEN, skin
testing with penicillin G and the major determinants
would be precluded. Although RAST testing was
helpful in this case, less than 20% of patients with a
history of penicillin have detectable penicillin specific
IgE antibodies at the time of testing.21 Also, lympho-
cyte transformation testing (LTT), a measurement of
proliferating T lymphocytes to a drug in vitro could
have been performed for confirmatory testing. How-
ever, this is not routinely performed because LTT re-
quires experience with cellular techniques, special
equipment, and the results are difficult to interpret.22
Also the positivity of LTT varies by the type of aller-
gic reaction being tested, more likely to be positive in
generalized exanthema such as maculopapular,
bullous, pustular, and less likely positive in TEN reac-
tions.22 Of note, our facility did not have access to
LTT. Cephalosporin skin tests are not routinely avail-
able, although anti-cephalosporin IgE antibody assays
are available to some clinicians in other countries. In
addition, specific haptenic determinants in hypersen-
sitivity are only recently being identified. For exam-
ple a degradation product of cefaclor and cephalexin,
a pyrazinone conjugate, has been identified as a po-
tential cephalosporin allergen by Venemalm in
2001.23
This case demonstrates the lack of a discrete algo-
rithm in the diagnosis of drug hypersensitivity. Com-
mercially available diagnostics to truly distinguish
classes of drug hypersensitivity and specific antibiotic
drug allergy are needed. A focused approach to the
cephalosporin reaction would have been helpful in
this case. However, cephalosporin allergenic determi-
nants have not been identified fully, and cepha-
losporin conjugates are reported to be unstable.24
Few studies have reported delayed hypersensitivity
reactions to cephalosporins, but patch testing for
cephalosporins have shown to be diagnostically use-
ful in case-reports.25 Although our correlation of this
case is primarily clinical, it demonstrates the variabil-
ity of beta lactam hypersensitivity and provides a
clinical example of concurrent IgE mediated and non-
IgE mediated reactions within a class of antibiotics. It
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further suggests a possible yet undelineated mecha-
nism of cross reactivity and hypersensitivity between
beta lactam classes.
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